Imidazole derivatives having affinity for alpha 2 receptors activity
View Patent ↗Novel prodrugs of MPV-2426, methods for preparing said prodrug forms, pharmaceutical compositions containing such prodrug forms, and methods for using the prodrug forms. A compound of general formula (I), or pharmaceutically acceptable salts or hydrates thereof, wherein R represents unsubstituted or substituted lower alkyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted lower alkylamino or a saturated five or six membered heterocyclic group containing one or two nitrogen atoms.
1. A prodrug 4-[6(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]1H-imidazole or a pharmaceutically acceptable salt thereof.
2. The prodrug according to claim 1 , wherein the compound is 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethy]-1H-imidazol-1-ium chloride.
3. A method for the treatment of hypertension, glaucoma, migraine, diarrhea, ischemia, addiction to a chemical substance, hypotension, shock, cardiopulmonary resuscitation, a withdrawal syndrome, congestive heart failure, anxiety, or for achieving sedation or analgesia, or for reducing nasal congestion, or for achieving anesthesia with an adjunct, which comprises administering to a mammal in need thereof an effective amount of a prodrug 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1H-imidazole or a pharmaceutically acceptable salt thereof.
4. The method according to claim 3 , wherein the prodrug is 4[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1H-imidazol-1-ium chloride.
5. A pharmaceutical composition which comprising a prodrug 4[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1H-imidazole or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable excipient.
6. The pharmaceutical composition according to claim 5 , wherein the prodrug is 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1H-imidazol-1-ium chloride.